CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(04): 469-480
DOI: 10.1055/a-1397-7170
GebFra Science

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Article in several languages: English | deutsch
Michael P. Lux
1  Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany
Andreas Schneeweiss
2  National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
Andreas D. Hartkopf
3  Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
Volkmar Müller
4  Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
Wolfgang Janni
5  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
Erik Belleville
6  ClinSol GmbH & Co. KG, Würzburg, Germany
Elmar Stickeler
7  Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany
Marc Thill
8  Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
Peter A. Fasching
9  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Hans-Christian Kolberg
10  Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
Michael Untch
11  Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany
Nadia Harbeck
12  Breast Center, Department of Gynecology and Obstetrics, CCC Munich, LMU University Hospital, Munich, Germany
Achim Wöckel
13  Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
Christoph Thomssen
14  Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
Carla E. Schulmeyer
9  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Manfred Welslau
15  Onkologie Aschaffenburg, Aschaffenburg, Germany
Friedrich Overkamp
16  OncoConsult Overkamp, Berlin, Germany
Florian Schütz
17  Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
Diana Lüftner
18  Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, University Medicine Berlin, Berlin, Germany
Nina Ditsch
19  Frauenklinik, Universitätsklinikum Augsburg, Augsburg, Germany
› Author Affiliations


In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.

Publication History

Received: 17 December 2020

Accepted after revision: 20 February 2021

Publication Date:
14 April 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany